Difference between revisions of "Team:BostonU/HP/Gold Integrated"

Line 234: Line 234:
 
   <p class="body-type mainwrap">Dr. Zaman covered two major topics in our discussion with him: accessibility and robustness. When addressing accessibility, he indicated that our device should be able to be used successfully by local health personnel. When designing new technologies, it is important that they fit easily into existing healthcare structure so that they can be adapted with ease. With regards to robustness, Dr. Zaman brought up a number of technical difficulties our technology might encounter if utilized outside of the lab. One issue when attempting to detect RNAs is that RNase enzymes, which are ubiquitous in the environment [1], are highly likely to contaminate RNA samples when not used in a sterile area. Due to the scarcity of sterile facilities needed to mitigate this issue in low-resource areas, RNAse contamination would be highly likely and thus render our device unusable. Dr. Zaman was unconvinced that our project, in its proposed form, would see success when used in the contexts that we were considering.</p>
 
   <p class="body-type mainwrap">Dr. Zaman covered two major topics in our discussion with him: accessibility and robustness. When addressing accessibility, he indicated that our device should be able to be used successfully by local health personnel. When designing new technologies, it is important that they fit easily into existing healthcare structure so that they can be adapted with ease. With regards to robustness, Dr. Zaman brought up a number of technical difficulties our technology might encounter if utilized outside of the lab. One issue when attempting to detect RNAs is that RNase enzymes, which are ubiquitous in the environment [1], are highly likely to contaminate RNA samples when not used in a sterile area. Due to the scarcity of sterile facilities needed to mitigate this issue in low-resource areas, RNAse contamination would be highly likely and thus render our device unusable. Dr. Zaman was unconvinced that our project, in its proposed form, would see success when used in the contexts that we were considering.</p>
 
  <p class="body-type mainwrap">&nbsp;</p>
 
  <p class="body-type mainwrap">&nbsp;</p>
<div class="figwrap mainwrap body-type">
 
</div>
 
 
<p class="body-type mainwrap">&nbsp;</p>
 
<p class="body-type mainwrap">&nbsp;</p>
 
<p class="body-type mainwrap">We then visited the Fraunhofer Center for Manufacturing Innovation’s Boston facility to discuss microfluidic systems and their applications. We learned that microfluidics can significantly increase efficiency of synthetic biologists’ work, since they can enable experiments to run semi-autonomously once all reagents are added. This automation allows scientists to take the time to work on other aspects of their projects such as data analysis and experimental design. Microfluidic chips are also portable and easy to use, which make them more accessible for point-of-care applications. These characteristics of microfluidics aligned with our initial intention of developing user-friendly diagnostic devices. However, through further conversations with Fraunhofer and our collaboration experience with <a href="https://2017.igem.org/Team:BostonU/Collaborations">BostonU Hardware,</a> we realized that with our resources and protocol, encapsulating our system in a microfluidic device would not be possible given the current state of our toehold technology. </p>
 
<p class="body-type mainwrap">We then visited the Fraunhofer Center for Manufacturing Innovation’s Boston facility to discuss microfluidic systems and their applications. We learned that microfluidics can significantly increase efficiency of synthetic biologists’ work, since they can enable experiments to run semi-autonomously once all reagents are added. This automation allows scientists to take the time to work on other aspects of their projects such as data analysis and experimental design. Microfluidic chips are also portable and easy to use, which make them more accessible for point-of-care applications. These characteristics of microfluidics aligned with our initial intention of developing user-friendly diagnostic devices. However, through further conversations with Fraunhofer and our collaboration experience with <a href="https://2017.igem.org/Team:BostonU/Collaborations">BostonU Hardware,</a> we realized that with our resources and protocol, encapsulating our system in a microfluidic device would not be possible given the current state of our toehold technology. </p>

Revision as of 20:55, 31 October 2017

INTEGRATED HUMAN PRACTICES